Pilot Study of Varenicline to Treat Opioid Dependence

The Role of Varenicline in Treating Opioid Dependence: A Pilot Study

The objective of this proposal is to explore the potential of varenicline as a pharmacotherapeutic agent for opioid dependence and addiction.

Inclusion criteria

• Age>=21 years
• Use of opioids at admission to PRC, with daily morphine equivalent dose>=60mg
• Be able and willing to participate fully in all aspects of the study including one month follow-up after completion of PRC
• Ability to provide informed consent

Exclusion criteria

• Currently using varenicline or other pharmacotherapy for nicotine dependence
• Currently pregnant, lactating, or likely to become pregnant during the trial and not willing to use an acceptable form of contraception;
• History of a major cardiovascular event in the past 6 months including unstable angina, acute myocardial infarction, stroke, or coronary angioplasty;
• Known varenicline allergy
• Use of any medication (e.g., methadone, Suboxone) as maintenance therapy for opiate addiction
• Identification of illicit drugs (e.g., marijuana, cocaine) on the baseline urine toxicology screen